Efficacy, safety and immunogenicity of HLX02 compared with reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a randomized phase 3 equivalence trial
mediaposted on 2021-03-16, 09:02 authored by Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yue’e Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Qingyu Wang
Article full text
The above Plain Language Summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.